Fluid delivery system container and method of use

JP2023551606A5Inactive Publication Date: 2024-11-29TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023556104
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-01
Filing Date
2021-11-22
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The administration of fluid therapeutics often requires mixing lyophilized active agents with solvents for reconstitution, which is typically done by individuals other than manufacturers, necessitating accurate and error-free mixing to ensure safety and efficacy.

Method used

The development of containers with multiple hingedly connected members that securely hold fluid delivery systems, such as syringes, in upright positions, allowing for easy mixing and reconstitution of active agents and solvents within a closed or open configuration, with features like grooves and recesses to securely retain and orient syringes and needles.

Benefits of technology

Ensures accurate and efficient reconstitution of fluid therapeutics, reducing errors and enhancing user convenience by providing a secure and organized system for mixing and storage of active agents and solvents, suitable for self-administration by patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A container for one or more fluid delivery systems is disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] FIELD OF THE DISCLOSURE The present disclosure relates generally to a container for a fluid delivery system. [Background technology]

[0002] Administration of a fluid therapeutic often involves mixing substances to form (e.g., reconstitute) a fluid therapeutic (e.g., a drug in liquid form), followed by delivery of the liquid drug to a patient. Reconstitution, as the term is used throughout this disclosure, is understood to be the process of mixing a lyophilized active agent with a solvent so that the active agent can be re-liquefied or reconstituted prior to injection. This process is common because lyophilizing (or freeze-drying) an active agent, such as a drug, biologic, or other therapeutic, preserves the drug's shelf life and allows the drug to be delivered to an end user for future mixing. However, because drug mixing is often expected to be completed by someone other than the manufacturer or pharmacist, care must be taken to ensure the mixing of the solvent and active agent is accurate and complete.

[0003] Syringes containing these fluid therapeutics are provided pre-loaded, ready for reconstitution and administration. In such cases, these syringes are sold to patients and caregivers as part of a treatment "container." These containers may include, for example, one or more syringes, disposable needles, cotton swabs, and other materials that form the treatment solution, as well as containers for housing these components. Summary of the Invention

[0004] The solutions of the present disclosure solve these and other problems in the art.

[0005] In some examples of the present disclosure, a container is disclosed that includes a closed configuration and an open configuration.

[0006] In some examples, a container is disclosed that includes a first member having an outer surface. A second member can be included with a substantially flat surface and hingedly connected to the first member. A third member can be included with an outer surface and hingedly connected to the second member, the third member including a substantially cylindrical recess configured to releasably retain a proximal end of a fluid delivery system such that the distal end of the fluid delivery system is oriented in an upright position during and / or after reconfiguration, where the fluid delivery system in the upright position is perpendicular to one or more fluid delivery systems releasably retained in the retention grooves of the first and / or third members. The container can be configured such that in a closed configuration, the outer surfaces of the first and third members are substantially parallel to each other and the outer edges of the first and third members are in contact with or immediately adjacent thereto to form a sealed housing. The container can be configured such that in an open configuration, the outer surfaces of the first, second, and third members are substantially planar to each other and face the same direction.

[0007] In some examples, the second member is disposed between the first member and the third member.

[0008] In some examples, the second member is orthogonal to the first and third members in the closed configuration.

[0009] In some instances, the first member is opposite the third member.

[0010] In some examples, the first, second and third members are integrally formed with one another.

[0011] In some instances, the substantially flat surface of the second member is free of structural members for releasably holding anything.

[0012] In some examples, the first member includes a plurality of grooves configured to frictionally engage and releasably secure a portion of any one of a plurality of fluid delivery systems, each of the plurality of fluid delivery systems being a pen-type injector.

[0013] In some examples, the grooves are configured to releasably retain at least six separate fluid delivery systems.

[0014] In some examples, the grooves are configured to releasably retain at least four separate fluid delivery systems.

[0015] In some examples, the groove releasably holds multiple fluid delivery systems such that each is aligned with the others and oriented parallel to the outer surface of the second member.

[0016] In some examples, the groove is formed (e.g., injection molded) into a tray coextensive with the first member, the groove configured to securely hold at least one of the plurality of fluid delivery systems in place during transport of the case. The tray may be removable from the first member.

[0017] In some examples, the third member can include a plurality of needle recesses configured to releasably retain sealed disposable needles for use at the distal end of the fluid delivery system.

[0018] In some instances, during and / or after reconstitution, the active agent and solvent contained in the distal ampoule portion of the fluid delivery system in the upright position are allowed to mix for a predetermined period of time.

[0019] In some examples, the substantially cylindrical recess is positioned adjacent a corner of the third member opposite the second member.

[0020] In some examples, each fluid delivery system of the container includes an ampoule pre-packaged with the active agent and solvent, so that the ampoule cannot be removed from the fluid delivery system by the end user.

[0021] In some examples, a container is disclosed that includes a first member including a substantially flat surface. A second member is also included with a substantially flat surface hingedly connected to the first member, the second member having a width greater than that of the first member. A third member is included with an outer surface and hingedly connected to the second member. The third member may include a plurality of grooves configured to frictionally engage and releasably secure any one of a plurality of fluid delivery systems, each of the plurality of fluid delivery systems being a pen-type syringe. The third member also includes a substantially cylindrical recess configured to releasably retain a proximal end of one of the fluid delivery systems during and / or after reconfiguration such that the distal end of the fluid delivery system is oriented in an upright position, the fluid delivery system in the upright position being perpendicular to the one or more fluid delivery systems releasably retained in the groove of the third member. The container is configured such that in a closed configuration, the first and third members are substantially parallel to each other and the edges of the first and third members contact or are immediately adjacent to each other to form a sealed housing. The container is configured such that, in the open configuration, the outer surfaces of the first, second and third members are substantially planar with respect to one another and face in the same direction.

[0022] In some examples, the second member is disposed between the first member and the third member.

[0023] In some examples, the substantially planar surfaces of the first member and the second member are contiguous with one another.

[0024] In some examples, the second member is orthogonal to the first and third members in the closed configuration.

[0025] In some examples, the first, second and third members are integrally formed with one another.

[0026] In some examples, the substantially flat surfaces of the first and second members are not configured with any structural members that releasably hold anything (e.g., coplanar flat surfaces with no structural features).

[0027] In some examples, the third member includes a plurality of grooves configured to frictionally engage and releasably secure a portion of any one of a plurality of fluid delivery systems, each of the plurality of fluid delivery systems being a pen-type injector.

[0028] In some examples, the grooves are configured to releasably retain at least six separate fluid delivery systems.

[0029] In some examples, the grooves are configured to releasably retain at least four separate fluid delivery systems.

[0030] In some examples, the groove releasably holds multiple fluid delivery systems such that each is aligned with the others and oriented parallel to the outer surface of the third member.

[0031] In some examples, the groove is formed (e.g., injection molded) into a tray coextensive with the third member, the groove configured to securely hold at least one of the plurality of fluid delivery systems in place during transport of the case. The tray may be removable from the third member.

[0032] In some instances, during and / or after reconstitution, the active agent and solvent contained in the distal ampoule portion of the fluid delivery system in the upright position are allowed to mix for a predetermined period of time.

[0033] In some examples, the substantially cylindrical recess is positioned adjacent a corner of the third member opposite the second member.

[0034] In some examples, each fluid delivery system includes an ampoule pre-packaged with the active agent and solvent, so that the ampoule cannot be removed from the fluid delivery system by the end user.

[0035] In some examples, the third member includes one or more grooves configured to frictionally engage and releasably secure a portion of the fluid delivery system, and the fluid delivery system is a pen syringe.

[0036] The groove is formed (e.g., injection molded) in a tray that is coextensive with the third member, the groove being configured to hold the fluid delivery system securely in place during shipping of the case. The tray may be removable from the third member.

[0037] In some examples, the third member includes a substantially cylindrical recess configured to releasably retain the proximal end of the fluid delivery system during and / or after reconfiguration such that the distal end of the fluid delivery system is oriented in an upright position, the fluid delivery system in the upright position being orthogonal to its position in the closed configuration when releasably retained within the groove of the third member.

[0038] In some instances, during and / or after reconstitution, the active agent and solvent contained in the distal ampoule portion of the fluid delivery system in the upright position are allowed to mix for a predetermined period of time.

[0039] In some examples, the substantially cylindrical recess is positioned adjacent a corner of the third member opposite the second member.

[0040] In some examples, the fluid delivery system includes an ampoule in which the active agent and solvent are pre-packaged, so that the ampoule cannot be removed from the fluid delivery system by the end user.

[0041] In some examples, a fluid delivery system of the present disclosure includes a housing, a cartridge holder fixedly mechanically coupled to the housing, and a cartridge disposed within an internal cavity of the cartridge holder. The cartridge can include a distal tip, a first stopper, a second stopper disposed between the distal tip and the first stopper, an active agent disposed between the distal tip and the second stopper, and a solvent disposed between the second stopper and the first stopper.

[0042] In some examples, the active agent includes lyophilized teduglutide.

[0043] In some examples, methods are disclosed that can include mixing an active agent of a fluid delivery system in any container of the present disclosure with a solvent disposed in the fluid delivery system, thereby generating a reconstituted liquid. The method can include disposing a proximal end of the fluid delivery system within a substantially cylindrical recess of the container for a predetermined period of time during and / or after reconstitution.

[0044] In some examples, the method can include disposing one or more fluid delivery systems within a recess or one or more grooves in the first and / or third members of the container.

[0045] In some examples, the method can include moving the container by a user from a closed configuration to an open configuration.

[0046] In some examples, the method can include moving the container by a user from an open configuration to a closed configuration.

[0047] In some examples, the method can include a step of selecting, by a user, one of a plurality of fluid delivery systems contained within the container, each of the plurality of fluid delivery systems containing a medication corresponding to one or more days of treatment.

[0048] In some examples, the method can include disposing a predetermined number of the plurality of fluid delivery systems in the container for a predetermined treatment period, which can be about one week, and the predetermined number can be at least four, six, or more or less than four fluid delivery systems.

[0049] In some examples, the method can include disposing a plurality of containers within a housing of the kit, the plurality of containers collectively containing about a one-month supply of the medication.

[0050] In some examples, the method may include selecting one of the plurality of containers; delivering a medication to a patient via a fluid delivery system of the selected container; removing a first or third member that already includes the plurality of fluid delivery systems upon use of each of the plurality of fluid delivery systems of the selected container; and then attaching a first or third member having another container of the plurality of containers to the selected container.

[0051] In some examples, the method may include selecting one of the plurality of containers; delivering a medication to a patient via a fluid delivery system of the selected container; removing a first or third member that already includes the plurality of fluid delivery systems upon use of each of the plurality of fluid delivery systems of the selected container; and then attaching a first or third member having another container of the plurality of containers to the selected container.

[0052] In some examples, the step of mixing the active agent with the solvent can include rotating the cartridge holder relative to the housing and axially moving the cartridge holder proximally through the housing from a first position to a second position; and rotating the cartridge holder relative to the housing and axially moving the button rod distally through the cartridge.

[0053] In some examples, the active agent may include lyophilized teduglutide, although other active agents are contemplated as needed or desired.

[0054] In some examples, a kit is disclosed that includes one or more containers according to the present disclosure.

[0055] In some examples, each container in the kit contains a predetermined supply of a fluid delivery system for a predetermined treatment period.

[0056] In some examples, each fluid delivery system of the kit contains about 3 ml of the agent contained in an active agent and a solvent.

[0057] In some examples, each fluid delivery system of the kit contains about 4 ml of the agent contained in the active agent and solvent.

[0058] In some instances, the kit is configured to provide a predetermined drug supply for a predetermined treatment period (e.g., about one month of drug therapy). For example, the kit can include at least four containers, each container of the kit containing about a one-week drug supply.

[0059] To the accomplishment of the foregoing and related ends, certain illustrative aspects are described herein in connection with the following description and the annexed drawings. These aspects are indicative, however, of but a few of the various ways in which the principles of the claimed subject matter can be employed and the claimed subject matter is intended to include all such aspects and their equivalents. Other advantages and novel features may become more apparent from the following detailed description when considered in conjunction with the drawings.

[0060] The above and further aspects of the present disclosure will be further discussed with reference to the following description in conjunction with the accompanying drawings, in which like numerals in the various figures indicate like structural elements and features. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the present disclosure. The drawings depict one or more embodiments of devices of the present disclosure by way of example only, and not by way of limitation. [Brief explanation of the drawings]

[0061] [Figure 1] FIG. 1 illustrates a container according to an example of the present disclosure. [Figure 2A] FIG. 1 illustrates a top perspective view of a container in an open configuration according to an example of the present disclosure. [Figure 2B] 2B is a top perspective view of the container of FIG. 2A in an open configuration, including various components, according to an example of the present disclosure. [Figure 2C] FIG. 2B is a top perspective view of the container of FIG. 2A in a closed configuration according to an example of the present disclosure. [Figure 3A] FIG. 1 illustrates a top perspective view of a container in an open configuration according to an example of the present disclosure. [Figure 3B] FIG. 3B is a top perspective view of the container of FIG. 3A in an open configuration, including various components, according to an example of the present disclosure. [Figure 3C] FIG. 3B is a top perspective view of the container of FIG. 3A in a closed configuration according to an example of the present disclosure. [Figure 4A] FIG. 1 illustrates a top perspective view of a container in an open configuration according to an example of the present disclosure. [Figure 4B] FIG. 4B is a top perspective view of the container of FIG. 4A in an open configuration, including various components, according to an example of the present disclosure. [Figure 4C] FIG. 4B is a top perspective view of the container of FIG. 4A in a closed configuration according to an example of the present disclosure. [Figure 5A] FIG. 1 illustrates a top perspective view of a container in an open configuration according to an example of the present disclosure. [Figure 5B] FIG. 1 illustrates a top perspective view of a container in a partially open configuration according to an example of the present disclosure. [Figure 5C] FIG. 1 illustrates a top perspective view of a container in a partially open configuration according to an example of the present disclosure. [Figure 5D] FIG. 1 illustrates a top perspective view of a container in a partially open configuration according to an example of the present disclosure. [Figure 6] Methods of using any of the containers of the present disclosure (e.g., a pen syringe prepackaged with an active agent that can be mixed with a solvent for delivery to a patient) are shown. DETAILED DESCRIPTION OF THE INVENTION

[0062] Although examples of the disclosed technology are described in detail herein, it should be understood that other examples are contemplated within the scope of the claimed invention. Accordingly, the disclosed technology is not intended to be limited in scope to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The disclosed technology may be in other embodiments and may be practiced or carried out in various ways.

[0063] It should also be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. By "comprising" or "containing" or "including," it is meant that at least the specified compounds, elements, particles, or method or use steps are present in a composition or article or method or use, but does not exclude the presence of other compounds, materials, particles, methods, or use steps, even if other such compounds, materials, particles, methods, or use steps have the same function as the specified one.

[0064] As used herein, the term "about" or "approximately" in connection with any numerical value or range indicates an appropriate dimensional tolerance that enables a portion or collection of components to function for its intended purpose as described herein. More specifically, "about" or "approximately" can refer to a range of values ​​of ±20% of the stated value; for example, "about 90%" can refer to a range of values ​​of 71% to 99%.

[0065] Furthermore, as used herein, the terms "patient," "host," "user," and "subject" refer to any human or animal subject, and while use of the subject invention in human patients represents a preferred example, it is not intended to limit the systems, methods, or uses to human use.

[0066] As used herein, the term "drug" or "medicament" refers to a liquid therapeutic agent used in a fluid delivery system, such as a pen injector (e.g., an auto-injector), associated with the treatment or cure of a disease or medical condition. Such a pharmaceutical agent may include, for example, a mixture of one part solvent and one part active ingredient that must be reconstituted before delivery to a patient, whereby the pharmaceutical agent is intended to treat a disease or medical condition, including, but not limited to, irritable bowel syndrome, although other conditions treatable with the fluid delivery system of the present disclosure (e.g., diabetes) are also contemplated.

[0067] In describing the examples, technical terms are used for clarity. Each term is intended to have the broadest meaning as understood by one of ordinary skill in the art and to include all technical equivalents that operate in a similar manner to achieve a similar purpose. It should also be understood that the reference to one or more steps of a method or use does not exclude the presence of additional or intervening method or use steps between those explicitly identified steps. The steps of the method or use may be performed in a different order than described herein without departing from the scope of the disclosed technology. Similarly, it should also be understood that the reference to one or more components in a device or system does not exclude the presence of additional or intervening components between those explicitly identified components.

[0068] The present disclosure relates to a container for one or more fluid delivery systems (e.g., auto-injectors or pen injectors), and related methods or uses. The present disclosure will be described with reference to examples, as shown in the accompanying drawings. References to "one example," "an example," "an example," or the like indicate that a described example may include a particular feature, structure, or characteristic, but not every example may necessarily include the particular feature, structure, or characteristic. Moreover, such phrases do not necessarily refer to the same example.

[0069] FIG. 1 is a top, front perspective view of a kit 150 including an exemplary container 200 slidably stored upright within the open kit. Another exemplary container 200 that can be stored within the kit 150 is shown adjacent to the kit 150 pulled out of the kit and placed on a treatment surface in an open configuration. In the open configuration, exemplary components stored therein are shown (e.g., syringe, disposable needle cap N, and instructions for use I). The kit 150 is particularly useful to patients and the like because it can include all components necessary for a patient to self-administer a subset of treatments, contained in a single container such as the container 200. The container 200 can be broadly understood as a carton or box, configured to house one or more auto-injectors pre-filled with medication. The container 200, as described in further detail below, can be of various shapes and sizes, can be made from various materials, and can have various opening and closing configurations.

[0070] While the container 200 may be generally rectangular, the shape of the container is not limited thereto, and it is contemplated that the containers of the present disclosure may include many shapes, such as cubes, triangles, spheres, cylinders, cones, or any other shape, as needed or desired. The kit 150 and / or container 200 may be made from a wide variety of materials. For example, the kit 150 and / or container 200 may be constructed as a composite or unitary structure using plastics (e.g., injection-molded polypropylene, polyvinyl chloride, polytetrafluoroethylene, polyethersulfone, polyethylene, polyurethane, polyetherimide, polycarbonate, polyetheretherketone, polysulfone, cyclic olefin polymers or cyclic olefin copolymers, etc.) and other materials, such as cardboard, paper, metal, glass, wood, etc. As shown, the kit 150 may be configured to include multiple containers 200 (e.g., five) that are slidably inserted into a drawer-like compartment through an open top end. However, the containers 200 may also include mechanisms for attaching each container 200 to one another within the kit 150 (eg, snap-fit ​​connectors, hook-and-loop fasteners, magnetic connectors and receivers, etc.).

[0071] 2A-2C, container 200 is shown in various configurations. For example, FIG. 2A shows container 200 in an open configuration without any external components, such as a fluid delivery system 500 (e.g., a pen injector), needle cap N, alcohol swab, or any other mechanism necessary for administration of a therapeutic agent from system 500 (including its various components). System 500 may be an auto-injector or pen injector pre-packaged with a medication for administration by a healthcare provider or self-administration by a patient, whereby such system 500 may include one or more features more clearly described in Appendix 1, which is incorporated by reference in its entirety from U.S. Provisional Patent Application No. 63 / 117,538, filed November 24, 2020, which is incorporated by reference as if set forth herein in its entirety. It is understood that system 500 need not, and cannot, be mechanically separated from its structural features to introduce or modify the medication pre-packaged therein. For example, the system 500 of the present disclosure, as well as the system 500 used with the various containers and systems herein, already contains all necessary agents, so that a separate vial of any separate or additional agent (e.g., solvent or active ingredient such as lyophilized teduglutide) is not required or usable with the system 500. The system 500 of the present disclosure can contain about 3 ml, about 4 ml, etc., defined by the active agent and solvent.

[0072] The vessel 200 can include multiple members 210, 220, 230. For example, the vessel 200 can include a first member 210 hingedly connected to a second member 220 and a third member 230 hingedly connected to the second member 220. However, the vessel 200 is not limited in this respect, and more or fewer members can be included in the vessel 200 as needed or desired. The members 210, 230 can include a processing surface having one or more sidewalls opposing thereto and a substantially flat lower surface configured to rest on another structural member.

[0073] The member 210 may include one or more sidewalls 217 extending upwardly away from the outer surface. The one or more sidewalls 217 may form cavities within which one or more grooves 215A, 215B, 215C may be disposed to releasably retain one or more systems 500. Each of the grooves 215A, 215B, 215C may be configured to releasably retain a portion of a system (e.g., groove 215A may be positioned to be releasably retained by a friction-engagement distal portion 505 of the system 500). More or fewer grooves 215A, 215B, 215C may be included as desired. The grooves 215A, 215B, 215C may also be sequentially spaced apart such that corresponding systems are similarly spaced apart and positioned in sequence. In some examples, the grooves 215A, 215B, 215C may be molded into an integrally formed tray that is removable from the one or more sidewalls 217.

[0074] The member 230 may include one or more sidewalls 237 extending upwardly away from the outer surface. The one or more sidewalls 237 may form one or more cavities 236, 232 in which one or more components for use with the system 500 (e.g., disposable needle caps N, alcohol swabs, etc.) can be temporarily stored. A substantially cylindrical recess 234 may be disposed between the one or more sidewalls 237 on the flat surface. The recess 234 may be configured to releasably hold one of the systems 500 in an upright position by the proximal portion 510 such that the distal portion 505 is oriented in an upright position during and / or after reconstitution. In the upright position shown in FIG. 2B , the system 500 is oriented perpendicular to one or more of the systems 500 releasably held in the grooves 215A, 215B, 215C. The system 500 in the upright position is also oriented perpendicular to the outer surface of the container 200 when placed in an open configuration on a flat preparation surface.

[0075] In contrast to members 210, 230, member 220 is substantially planar and lacks outwardly extending structural members. Rather, member 220 is hingedly connected to member 210 by hinge mechanism 221 and to member 230 by hinge mechanism 231. As shown, each of mechanisms 221, 231 is formed by a fold. However, other pivotable mechanisms or hinges are contemplated as needed or desired.

[0076] 2B, container 200 is shown with multiple systems 500 disposed within grooves 215A, 215B, 215C of member 210. Each of systems 500 is pre-packaged with a medication and awaits reconstitution for delivery to a patient. A user can select any one of systems 500 from member 210 and then position the selected system 500 such that a proximal portion 510 of system 500 is disposed within recess 234 of third member 230 during and / or after reconstitution.

[0077] In some examples, prior to placing portion 510 within recess 234, a user can prime system 500 by rotating the cartridge holder relative to the housing of system 500, moving the cartridge holder axially proximally through the housing from a first position to a second position. The user can continue to rotate the cartridge holder relative to the housing, which causes the button rod to move axially distally through the cartridge, thereby mixing the active agent disposed in distal portion 505 of system 500 between the distal tip of the cartridge and the second stopper with the solvent disposed between the second stopper and the first stopper. A reconstituted liquid is then created within system 500. At this point, proximal portion 510 (e.g., the button end of system 500) can be placed within recess 234 for a predetermined period of time until ready for injection into a patient. It is understood that portions 505, 510 in some examples are permanently attached, provided they are non-removable from one another once placed within container 200 prior to receipt by an end user.

[0078] Container 200 can include six syringe systems 500 within member 210, such that each system 500 collectively contains medication for approximately one week of treatment (e.g., each system 500 can contain enough medication for one day). Similarly, because container 200 can contain enough daily medication for approximately one week, kit 150 shown in FIG. 1 can be sent to an end user to easily manage a month's supply of medication for a given health condition. It is understood that member 210 can also be removed from container 200 after the user has used up the system 500's supply (e.g., at the end of a week) and can be attached from another container 200 temporarily stored within kit 150. Of course, kit 150 can include more or fewer containers 200 to accommodate longer or shorter periods of treatment (e.g., if more than one month's supply of medication is desired).

[0079] FIG. 2C shows container 200 in a closed configuration, with only the outer surface shown. Flat surface 213 can extend from member 210, previously shown in FIG. 2A, opposite member 230. A hinge or fold 211 can be present where surface 213 extends from member 210, after which or because of which member 210 pivots about hinges 221, 231 and closes around opposing sidewall 237 of member 230, as shown in FIG. 2C. Optionally, as clearly shown in FIG. 2C, tab 242 can extend from surface 213 to facilitate a user's movement of container 200 between the open and closed configurations. Tab 242 can be coupled to a receiver (not shown) on container 200, including a snap receiver, magnetic receiver, or other removable fastener that facilitates quick release and secure fastening. As shown, member 210 can be the top half of container 200 in the closed configuration, and member 230 can be the bottom half. The upper surfaces formed by walls 217, 237 may contact one another to form an interior cavity in a closed configuration. Member 220 in Figure 2C is not shown, but forms a rear book hinge wall that bridges members 210, 230.

[0080] 3A-3C, the container 300 is shown in various configurations. For example, FIG. 3A shows the container 300 in an open configuration without any external components, such as the system 500, needle cap N, alcohol swab, or any other mechanism necessary for administering a therapeutic agent from the system 500 (including its various components). The container 300 can include multiple members 310, 320, 330. For example, the container 300 can include a first member 310 hingedly connected to a second member 320 and a third member 330 hingedly connected to the second member 320. However, the container 300 is not limited in this respect, and more or fewer members can be included in the container 300 as needed or desired. The members 310, 330 can include a substantially flat lower surface configured to rest on a treatment surface.

[0081] The member 330 may include one or more sidewalls 337 extending upwardly away from the outer surface. The one or more sidewalls 337 may form one or more cavities 335, 332, 333 within which one or more systems 500 or components for use with the system 500 (e.g., disposable needle caps N, alcohol swabs, etc.) may be temporarily stored. A substantially cylindrical recess 334 may be disposed between the one or more sidewalls 337 on the flat surface (e.g., adjacent to one of the cavities 335, 332, 333). The recess 334 may be configured to releasably hold one of the systems 500 in an upright position by the proximal portion 510 such that the distal portion 505 is oriented in an upright position during and / or after reconfiguration. In the upright position shown in FIG. 3B , the system 500 is oriented perpendicular to one or more of the systems 500 it previously held while releasably held within the cavities 335, 332, 333. The system 500 in the upright position is also oriented perpendicular to the outer surface of the container 300 when placed in an open configuration on a flat preparation surface.

[0082] In contrast to member 330, members 310, 320 are both substantially flat and lack outwardly extending structural members. Rather, member 320 is hingedly connected to member 310 by hinge mechanism 321 and to member 330 by hinge mechanism 331. As shown, each of mechanisms 321, 331 is formed by a fold. However, other pivotable mechanisms or hinges are contemplated as needed or desired. Referring to FIG. 3B, container 300 is shown with multiple systems 500 disposed within cavity 335 of member 330. Each of systems 500 is pre-packaged with a medicament containing the solvent and active ingredient required for each system 500, awaiting reconstitution for delivery to a patient. The user can select any one of the systems 500 from the members 330 and then position the selected system 500 so that the proximal portion 510 of the system 500 is positioned within the recess 334 of the third member 330 during and / or after reconfiguration, as previously discussed.

[0083] FIG. 3C shows container 300 in a closed configuration, with only the exterior surface shown. In the closed configuration, tab 342 can extend from surface 313, as clearly shown in FIG. 3C, to facilitate a user's movement of container 300 between the open and closed configurations. As shown, the upper surface formed by wall 337 can contact the interior surface of 310 to form an interior cavity in the closed configuration. Member 320 in FIG. 3C is not shown, but it forms a rear book hinge wall bridging members 310 and 330.

[0084] 4A-4C, the container 400 is shown in various configurations. For example, FIG. 4A shows the container 400 in an open configuration without any external components, such as the system 500, needle cap N, alcohol swab, or any other mechanism necessary for administering a therapeutic agent from the system 500 (including its various components). The container 400 can include multiple members 410, 420, 430. For example, the container 400 can include a first member 410 hingedly connected to a second member 420 and a third member 430 hingedly connected to the second member 420. However, the container 400 is not limited in this respect, and more or fewer members can be included in the container 400 as needed or desired. The members 410, 430 can include a substantially flat lower surface configured to rest on a treatment surface.

[0085] The member 430 may include one or more sidewalls 437 extending upwardly away from the outer surface. The one or more sidewalls 437 may form one or more cavities 435, 432, 433. The container 400 is configured to house only one system 500 within the hollow container 435, as shown in FIG. 4B . However, ancillary components that aid in use with the system 500 (e.g., disposable needle caps N, alcohol swabs, etc.) may be temporarily stored within the cavities 433, 432. A substantially cylindrical recess 434 may be disposed between the one or more sidewalls 437 on the flat surface (e.g., adjacent to one of the cavities 435, 432, 433). The recess 434 may be configured to releasably hold the system 500 in an upright position by the proximal portion 510 such that the distal portion 505 is oriented in an upright position during and / or after reconfiguration. 4B, the system 500 is oriented perpendicular to the orientation system 500 previously had while releasably held within cavity 435. System 500 in the upright position is also oriented perpendicular to the outer surface of container 400 when placed in an open configuration on a flat preparation surface.

[0086] In contrast to member 430, members 410, 420 are both substantially flat and lack outwardly extending structural members. Rather, member 420 is hingedly connected to member 410 by hinge mechanism 421 and to member 430 by hinge mechanism 431. As shown, each of mechanisms 421, 431 is formed by a fold. However, other pivotable mechanisms or hinges are contemplated as needed or desired.

[0087] Referring to FIG. 4B, the container 400 is shown with only the system 500 disposed within the cavity 435 of the member 430. FIG. 4C shows the container 400 in a closed configuration, with only the exterior surface shown. In the closed configuration, as clearly shown in FIG. 4C, a tab 442 can extend from the surface 413, facilitating a user's movement of the container 400 between the open and closed configurations. As shown, the upper surface formed by the wall 437 can contact the interior surface of the member 410 to form an interior cavity in the closed configuration. Although not shown, member 420 in FIG. 4C forms a rear book hinge wall bridging members 410 and 430.

[0088] 5A-5D, additional embodiments of containers are shown in various configurations. For example, FIG. 5A shows container 500A in an open configuration without any external components, such as system 500, needle cap N, alcohol swab, or any other mechanism necessary for administering a therapeutic agent from system 500 (including its various components). Container 500A can be seen to include a substantially planar member 510A hingedly connected to member 530A, which includes features similar to member 330 described above. In the closed configuration, member 510A can pivot about a shared axis to cover member 530A.

[0089] 5B shows container 500B in a partially open configuration, without any external components such as system 500, needle cap N, alcohol swab, or any other mechanism necessary for administering a therapeutic agent from system 500 (including its various components). Container 500B can be seen to include a removable member 510B that can fit over member 530B, which can include features similar to member 330 described above. Member 530B can include a stepped surface extending outward from its sidewall, upon which member 510B can rest snugly in a closed configuration, similar to a shoebox.

[0090] 5C shows container 500C in a partially open configuration, without any external components such as system 500, needle cap N, alcohol swab, or any other mechanism necessary for administering a therapeutic agent from system 500 (including its various components). Container 500C can be seen to include member 510C, which can include a single open end through which member 530C can slide in and out like a drawer. Member 530C can include similar features to member 330 described above.

[0091] 5D shows container 500D in an open configuration, without any external components such as system 500, needle cap N, alcohol swab, or any other mechanism necessary for administration of a therapeutic agent from system 500 (including its various components). Container 500D can be seen to include lid member 510D hingedly connected to member 530D, which includes features similar to member 430 described above. In the closed configuration, member 510D can pivot to cover member 530D.

[0092] 6 illustrates a disclosed method 600. Method 600 can include mixing 610 an active agent of a fluid delivery system in any container of the present disclosure with a solvent disposed within the fluid delivery system, thereby generating a reconstituted liquid. Method 600 can also include disposing 620 a proximal end of the fluid delivery system within a substantially cylindrical recess of the container for a predetermined period of time during and / or after reconstitution.

[0093] It should be understood that the recitation of one or more steps of a method, including method 600, does not exclude the presence of additional or intervening method steps between those explicitly identified steps. Method steps may be performed in a different order than described herein without departing from the scope of the disclosed technology.

[0094] In this regard, the method 600 may include disposing one or more fluid delivery systems within a recess or one or more grooves in the first and / or third members of the container.

[0095] The method 600 can also include moving the container from a closed configuration to an open configuration by the user.

[0096] The method 600 may also include the step of moving the container by the user from an open configuration to a closed configuration.

[0097] The method 600 may also include a step of selecting, by a user, one of a plurality of fluid delivery systems contained within the container, each of the plurality of fluid delivery systems containing medication corresponding to one or more days of treatment.

[0098] Method 600 can also include disposing a predetermined number of the plurality of fluid delivery systems in the container for a predetermined treatment period, which can be about one week, and the predetermined number can be at least four, six, or more or less than four fluid delivery systems.

[0099] The method 600 can also include disposing a plurality of containers within the housing of the kit, the plurality of containers collectively containing approximately one month's supply of medication.

[0100] Method 600 may also include selecting one of the plurality of containers; delivering a medication to a patient via a fluid delivery system of the selected container; removing a first or third member that already includes the plurality of fluid delivery systems upon use of each of the plurality of fluid delivery systems of the selected container; and then attaching a first or third member having another container of the plurality of containers to the selected container.

[0101] The method 600 can include selecting one of the plurality of containers; delivering the agent to the patient via the fluid delivery system of the selected container; removing the first or third member that already includes the plurality of fluid delivery systems upon use of each of the plurality of fluid delivery systems of the selected container; and then attaching the first or third member having another of the plurality of containers to the selected container. In some examples, the step of mixing the active agent with the solvent in the method 600 can include rotating the cartridge holder relative to the housing and axially moving the cartridge holder proximally through the housing from a first position to a second position; and rotating the cartridge holder relative to the housing and axially moving the button rod distally through the cartridge.

[0102] In describing the exemplary embodiments, technical terminology is used for the sake of clarity. Each term is intended to have the broadest meaning as understood by one of ordinary skill in the art and to encompass all technical equivalents that operate in a similar manner to accomplish a similar purpose. The descriptions contained herein are examples of embodiments of the present disclosure and are not intended to limit the scope of the invention in any way.

[0103] While specific examples of the present disclosure are described, various modifications can be made to the apparatus and methods without departing from the scope and spirit of the present disclosure. For example, while the examples described herein refer to specific components of a container, the present disclosure includes other examples that utilize various combinations of components to achieve the described functions, utilize alternative materials to achieve the described functions, combine components from various examples with known components, and the like. The present disclosure contemplates substituting other well-known, commercially available products for the components shown herein. These modifications will often be apparent to those skilled in the art to which the present disclosure pertains, and are intended to be included within the scope of the claims.

Claims

1. A container comprising: a first member including an exterior surface and a plurality of grooves opposite said exterior surface, said plurality of grooves configured to frictionally engage and releasably secure a portion of any one of a plurality of fluid delivery systems, each of said plurality of fluid delivery systems being a pen-type injector; a second member having a substantially flat surface and hingedly connected to the first member; a third member having an outer surface and hingedly connected to the second member, the third member including a substantially cylindrical recess configured to releasably retain a proximal end of one of the plurality of fluid delivery systems such that during and / or after reconfiguration a distal end of the fluid delivery system is oriented in an upright position, the fluid delivery system in the upright position being orthogonal to one or more of the plurality of fluid delivery systems releasably retained within the groove; the container is configured such that in a closed configuration, the outer surfaces of the first and third members are substantially parallel to one another and outer edges of the first and third members are in contact or immediately adjacent thereto to form a sealed housing; The container is configured such that in an open configuration, the outer surfaces of the first, second and third members are substantially planar with respect to one another and face in the same direction.

2. The container of claim 1 , wherein the second member is disposed between the first member and the third member.

3. The container of claim 1 , wherein the grooves are configured to releasably retain at least four separate fluid delivery systems.

4. The container of claim 1 , wherein the groove releasably holds the plurality of fluid delivery systems such that each is aligned with the others and oriented parallel to the outer surface of the second member.

5. 2. The container of claim 1, wherein the groove is formed in a tray coextensive with the first member, the groove being configured to securely hold at least one of the plurality of fluid delivery systems in place during transport of the container.

6. The third member includes: The container of claim 1 , comprising a plurality of needle recesses configured to releasably retain sealed disposable needles for use at a distal end of the fluid delivery system.

7. 7. The container of claim 6, whereby during and / or after reconstitution, the active agent and solvent contained in the distal ampoule portion of the fluid delivery system in the upright position are mixed for a predetermined period of time.

8. 7. The container of claim 6, wherein the substantially cylindrical recess is positioned adjacent a corner of the third member opposite the second member.

9. 10. The container of claim 1, wherein each said fluid delivery system includes an ampoule prepackaged with an active agent and a solvent, whereby the ampoule cannot be removed from the fluid delivery system by an end user.

10. The fluid delivery system comprises: Housing and a cartridge holder fixedly connected to the housing; a cartridge disposed within an interior cavity of a cartridge holder, said cartridge comprising: a distal tip; and A first stopper; a second stopper disposed between the distal tip and the first stopper; an active agent disposed between the distal tip and the second stopper; and a solvent disposed between the second stopper and the first stopper.

11. The container of claim 10, wherein the active agent comprises lyophilized teduglutide.

12. 1. A method, comprising: placing a predetermined number of said plurality of fluid delivery systems within the container of claim 10 for a predetermined treatment period; selecting, by a user, one of the plurality of fluid delivery systems, each of the plurality of fluid delivery systems including a medication corresponding to one or more days of treatment; mixing an active agent of a fluid delivery system in the container with a solvent disposed in the fluid delivery system, thereby generating a reconstituted liquid; disposing a proximal end of the fluid delivery system within a substantially cylindrical recess of the container for a predetermined period of time during and / or after reconstitution; delivering a medication to a patient via the selected one of the plurality of fluid delivery systems; removing the first or third member that already contains the plurality of fluid delivery systems upon use of each of the plurality of fluid delivery systems of the container; and thereafter The method further comprising attaching another first or third member to the container.

13. 13. The method of claim 12, wherein the active agent comprises lyophilized teduglutide.

14. 13. The method of claim 12, wherein the predetermined treatment period is one week and the predetermined number is at least four fluid delivery systems.

15. A kit comprising one or more containers according to claim 11.

16. 16. The kit of claim 15, wherein each of the containers contains a predetermined supply of a fluid delivery system for a predetermined treatment period.

17. 17. The kit of claim 16, wherein each of the fluid delivery systems contains 3 ml of the agent contained in the active agent and the solvent.

18. 17. The kit of claim 16, wherein each of the fluid delivery systems contains 4 ml of the agent contained in the active agent and the solvent.

19. 17. The kit of claim 16, wherein the predetermined treatment period is one month, and the kit comprises at least four containers, each of the containers in the kit containing a supply lasting one week.

20. The container of claim 5, wherein the tray is removable from the first member and replaceable with an auxiliary tray having a second plurality of fluid delivery systems.